TL;DR
Ascletis has submitted two IND applications to the U.S. FDA for new obesity treatments. The applications involve a monthly peptide injection and a co-formulated injectable, marking a significant step in their development pipeline.
Ascletis has submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for novel obesity treatments, marking a key milestone in their development efforts. The filings include a once-monthly peptide injection, ASC36, and a co-formulation, ASC36_35, combining ASC36 with a peptide targeting GLP-1R and GIPR. This development is significant as it advances Ascletis’s pipeline toward clinical testing in the United States, where obesity remains a major health challenge.
The first application pertains to ASC36, a peptide-based medication designed as a once-monthly injection targeting obesity through a peptide amylin receptor agonist mechanism. The second application involves ASC36_35, a co-formulated drug combining ASC36 with a peptide that acts on GLP-1 and GIP receptors, which are well-established targets in obesity and diabetes treatments. Both applications were submitted to the FDA by Ascletis Pharma Inc., a Chinese biopharmaceutical company focused on metabolic and infectious diseases.
According to the company’s announcement, these submissions are part of their strategy to expand their presence in the U.S. market and advance innovative therapies for obesity, a condition affecting millions globally. The IND filings indicate that Ascletis has completed preclinical studies demonstrating safety and efficacy, and now seeks approval to begin human trials. It is not yet clear when the FDA will review or approve these applications, or when clinical trials might commence.
Potential Impact on Obesity Treatment Landscape
The submission of these IND applications signals Ascletis’s entry into the competitive U.S. obesity treatment market, which is currently dominated by GLP-1 receptor agonists like semaglutide. If approved, their novel peptide-based therapies could offer alternative options, potentially with different dosing schedules or mechanisms of action. This move underscores ongoing innovation in obesity pharmacotherapy and may influence future drug development strategies, especially for companies aiming to introduce more effective or convenient treatments.
NAD+ Peptide Vial, (>99% Purity), 10mL Sterile Vial, (500mg), Lab-Grade Research Peptide
500mg NAD+ in lyophilized powder form (>99% purity)
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Ascletis’s Development Pipeline and Market Position
Ascletis has been primarily focused on infectious diseases and hepatitis C, but has expanded into metabolic disorders in recent years. The company’s pipeline includes several candidates in different stages of development, with these two IND filings representing their latest efforts in obesity. The company’s previous work in peptide therapeutics and receptor agonists provides a foundation for these new applications. Globally, obesity treatments are a rapidly evolving field, with several new drugs approved in recent years, increasing the significance of Ascletis’s progress in this area.
Prior to these filings, Ascletis has not had any drugs approved in the U.S., and it remains to be seen how their new candidates will perform in clinical trials and regulatory review.
“The submission of these IND applications marks an important milestone for Ascletis, as we move closer to bringing innovative obesity treatments to patients in the U.S.”
— Dr. Jinzi Wu, CEO of Ascletis
GLP-1 GIP receptor agonist injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Regulatory and Clinical Trial Timelines Still Unclear
It is not yet confirmed when the FDA will review or approve the IND applications, nor when clinical trials might begin. The success of these filings depends on FDA review outcomes and subsequent trial results, which remain uncertain at this stage.
ZEPBOUND 10 MG/0.5 ML PEN INJ
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps Include FDA Review and Clinical Trial Initiation
Ascletis will await FDA feedback on their IND submissions, which will determine the timeline for starting human trials. The company may also need to address any additional requests or modifications from regulators before progressing further. Monitoring updates from Ascletis and the FDA will be key to understanding when these treatments could enter clinical testing.
peptide-based weight management injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the main features of Ascletis’s new obesity treatments?
The treatments include a once-monthly peptide injection, ASC36, and a co-formulated injectable combining ASC36 with a peptide targeting GLP-1 and GIP receptors. Both are designed to aid weight loss through receptor activation.
What does submitting an IND application mean for Ascletis?
Submitting an IND indicates that Ascletis has completed preclinical studies and is seeking FDA approval to begin human clinical trials for their new drugs.
When might clinical trials for these treatments start?
The exact timeline depends on FDA review outcomes. No specific dates have been announced yet, and approval processes can take several months to over a year.
How might these treatments differ from existing obesity drugs?
If approved, these peptide-based injections could offer alternative mechanisms of action or dosing schedules compared to current therapies like semaglutide, potentially improving patient adherence or efficacy.
What are the potential risks or challenges for Ascletis in this process?
The main challenges include obtaining FDA approval, demonstrating safety and efficacy in clinical trials, and competing with established obesity treatments in the market.
Source: primary
